Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Second edition of Antibodies: An essential resource for molecular biology, immunology, and cell culture lab

The now classic lab manual Antibodies, by Harlow and Lane, has been revised, extended, and updated by Edward Greenfield of the Dana-Farber Cancer Center, with contributions from other leaders in the field.

19 Sep 2013

First clinical trials to diagnose and treat Alzheimer’s disease

More than a century ago, Alois Alzheimer, a Bavarian physician, first identified the neurodegenerative brain condition that came to be known as Alzheimer's disease. Finding ways to diagnose and treat this disease has frustrated scientists and clinicians ever since.

19 Sep 2013

Wayne State University initiates groundbreaking multiple sclerosis study

A groundbreaking study in multiple sclerosis focusing on "remyelination in the brain" has been initiated by Omar Khan, M.D., professor and chair of neurology at the Wayne State University School of Medicine.

19 Sep 2013

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody product to enter the clinic this year.

17 Sep 2013

Vanderbilt examines ability of drug abatacept to prevent type 1 diabetes

Vanderbilt's Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

17 Sep 2013

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics AG and The Leukemia & Lymphoma Society today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma patients for whom currently available treatments have failed.

16 Sep 2013

Diabetes Mellitus Incidence Cohort Registry study reveals mixture of diabetes phenotypes

The DiMelli (Diabetes Mellitus Incidence Cohort Registry) study examines the frequency and characteristics of diabetes phenotypes in children and young adults below the age of 20. The study was commissioned to investigate the increasing incidence of diabetes mellitus, particularly in childhood and early adulthood. The project is funded by the German Center for Diabetes Research (DZD).

13 Sep 2013

Helper T cells important for AIDS vaccine development

A major new finding that will significantly advance efforts to create the world's first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.

13 Sep 2013

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Amgen today announced the publication of a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer.

12 Sep 2013

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

12 Sep 2013

New antibody could prevent Candida infections in patients who receive central lines

A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.

12 Sep 2013

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry assay by the Chinese Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI (crizotinib).

12 Sep 2013

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

...

10 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

New technology to diagnose influenza quickly

A new technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs slams shut and sick people spread the virus to others, scientists reported here today. In a presentation at the 246th National Meeting & Exposition of the American Chemical Society (ACS), they described how it also could determine the specific strain of flu virus and help select the most effective drug for treatment.

10 Sep 2013

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PharmAthene, Inc. announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus – ACT international anthrax conference in Victoria, British Columbia, Canada.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Study finds similar antibody levels among 4 PCV13 immunization schedules

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

5 Sep 2013

Antibody News and Research

Further Reading

Second edition of Antibodies: An essential resource for molecular biology, immunology, and cell culture lab

First clinical trials to diagnose and treat Alzheimer’s disease

Wayne State University initiates groundbreaking multiple sclerosis study

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

Vanderbilt examines ability of drug abatacept to prevent type 1 diabetes

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Diabetes Mellitus Incidence Cohort Registry study reveals mixture of diabetes phenotypes

Helper T cells important for AIDS vaccine development

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

New antibody could prevent Candida infections in patients who receive central lines

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

Roche Signs Up To $422.5M Collaboration With Inovio

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

New technology to diagnose influenza quickly

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Study finds similar antibody levels among 4 PCV13 immunization schedules

Antibodies eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News